FINWIRES · TerminalLIVE
FINWIRES

歐洲、中東和非洲地區天然氣市場最新動態:霍爾木茲氣田重新開放緩解供應擔憂,價格下滑

-- 週五盤後交易中,歐洲天然氣期貨價格持續下跌。先前,美國總統川普和伊朗官員宣布霍爾木茲海峽已重新開放商業航運,導致天然氣期貨價格早盤大幅下挫。 荷蘭TTF近月合約下跌8.03%,至每兆瓦時39.015歐元(46.04美元);英國NBP期貨下跌7.432%,至每熱量單位98.40便士(1.33美元)。 天然氣價格一度跌破每兆瓦時39歐元,創下自2月中東衝突爆發前的最低水準。 這次拋售潮源自於伊朗外交部長阿巴斯·阿拉格奇的表態。阿拉格奇表示,在目前的停火條件下,霍爾木茲海峽仍完全開放。這項聲明緩解了市場對這條全球最重要的能源運輸通道之一可能長期中斷的擔憂,並促使交易員平倉近期衝突期間累積的風險溢價。 川普的言論也影響了市場情緒,他暗示伊朗的讓步可能有助於在外交上取得更廣泛的進展,但他同時指出,在談判結束前,美國海上封鎖將繼續實施。 在緊張局勢最嚴重的時候,霍爾木茲海峽附近的航運中斷影響了全球約20%的液化天然氣(LNG)流量。供應衝擊導致亞洲進口量降至多年來的最低水平,間接使歐洲買家受益,減少了競爭。 Trading Economics表示,隨著這些風險的消退,交易員正在重新評估供應前景。 疲軟的需求基本面進一步打壓了價格。歐洲部分地區異常溫暖的天氣和強勁的風力發電降低了對天然氣發電的依賴。 據歐洲天然氣基礎設施協會(Gas Infrastructure Europe)稱,由於庫存水平仍處於較低水平,佔總容量的29.55%,而去年同期接近36%,較低的價格可能有助於在冬季到來之前重建庫存。 人們對夏季能源供應的擔憂仍然存在。大氣氣象公司Atmospheric G2週四在社群媒體上發文指出,阿爾卑斯山降水有限,積雪量低,增加了水力發電量下降的風險,並可能導致極端高溫或乾旱時期電力市場供應緊張。 美國國家氣象局4月9日表示,厄爾尼諾現象可能在2026年5月至7月間出現,並持續到年底。預報員稱,這將增加夏季氣溫高於往年同期的可能性,尤其是在南歐地區,這可能會進一步影響能源需求和市場波動。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA